Table 2.
Change in Isc in anti-CD3-injected mice
Sham-injected | Anti-CD3 mAb-injected | |||||
---|---|---|---|---|---|---|
G (mS cm−2) | Basal Isc | cAMP-stimulated Isc | G (mS cm−2) | Basal Isc | cAMP-stimulated Isc | |
Basal | 11.5 ± 1.1 | 0.6 ± 2.1 | 3.0 ± 0.16 | 13.3 ± 1.4 | 2.1 ± 0.14 | 2.5 ± 0.18 |
NPPB | 12.6 ± 1.1ns | 0.3 ± 0.9* | 0.3 ± 0.04* | 13.5 ± 1.1ns | 0.4 ± 0.05* | 0.4 ± 0.05* |
Glibenclamide | 12.1 ± 1.2ns | 0.4 ± 1.9** | 0.3 ± 0.06** | 14.1 ± 1.1ns | 0.3 ± 0.05** | 0.24 ± 0.06** |
Experiments were done in the presence of luminal Cl− and HCO3−-containing Ringer solution. Isc (μEq h−1 cm2) after addition of 10 μm forskolin are taken from the highest values. Values represent mean ± s.e.m.n = 12 in the basal group and n = 6 in which blockers were added.
P < 0.001, comparison between presence and absence (basal) of NPPB.
P < 0.001, comparison between presence and absence (basal) of glibenclamide. ns = no significant difference between the groups.